Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Contraception
- Antibiotics at the time of induced abortion: the case for universal prophylaxis based on a meta-analysis.Obstet Gynecol. 1996; 87: 884-890
- Early pregnancy termination with mifepristone and misoprostol in the United States.N Engl J Med. 1998; 338: 1241-1247
- Mifepristone and misoprostol for early medical abortion: 18 months experience in the United States.Contraception. 2003; 67: 463-465
- Infection after medical abortion: a review of the literature.Contraception. 2004; 70: 183-190
- Safety of mifepristone abortions in clinical use.Contraception. 2005; 72: 175-178
- Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion.N Engl J Med. 2005; 353: 2352-2360
- Letter to the editor on deaths associated with medication abortion.Contraception. 2005; 72: 319
http://www.cdc.gov/hai/organisms/csordellii.html. Accessed November 15, 2013.
- Sexually Transmitted Disease Surveillance 2006 Supplement, Gonococcal Isolate Surveillance Project (GISP) Annual Report 2006.U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, GA2008
- Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial.Obstet Gynecol. 2008; 112: 1303-1310
- Rates of serious infection after changes in regimens for medical abortion.N Engl J Med. 2009; 361: 145-151
- Pregnancy-related mortality in the United States, 1998 to 2005.Obstet Gynecol. 2010; 116: 1302-1309
- Effectiveness of medical abortion with mifepristone and buccal misoprostol through 59 gestational days.Contraception. 2009; 80: 282-286
- Significant adverse events and outcomes after medical abortion.Obstet Gynecol. 2013; 121: 166-171
☆Funding: This work was supported in part by the Eunice Kennedy Shriver National Institute of Child Health and Human Development grant for Infrastructure for Population Research at Princeton University, Grant R24HD047879 (JT).
☆☆Disclaimer: The findings and conclusions in this presentation are those of the authors and do not necessarily represent the views of Planned Parenthood Federation of America.
★Disclosures: The authors report no financial conflicts of interest.